Pfizer announced that its experimental drug, ponsegromab, has demonstrated positive results in a midstage clinical trial for cancer cachexia—a severe condition causing appetite and weight loss in cancer patients. This breakthrough could lead to the first approved treatment specifically targeting this debilitating syndrome.
Key Findings
In the trial, patients with cancer cachexia who received ponsegromab showed improvements in body weight, muscle mass, quality of life, and physical function. The drug, a monoclonal antibody, targets growth differentiation factor 15 (GDF-15), a protein influencing appetite.
Clinical Impact
Cancer cachexia affects approximately 9 million people globally and significantly reduces survival rates by making cancer treatments less effective. Patients typically experience a loss of 5% or more of their body weight over six months, along with severe fatigue.
Trial Results
The phase two trial involved 187 patients with non-small cell lung cancer, pancreatic cancer, or colorectal cancer. After 12 weeks, those on the highest dose of 400 mg of ponsegromab experienced a 5.6% weight increase compared to the placebo group. Lower doses also showed positive results, with weight gains of 3.5% and 2%.
Future Plans
Pfizer aims to start late-stage trials in 2025. The drug is also being tested for cachexia in heart failure patients. Encouragingly, no significant side effects were reported, suggesting a favorable safety profile.
↔ 
↔ 
↔ 
↔ 
↔ 
↔ 
↔ 
↔ 
↔ 
↔ 
→ 
→ 
→ 
→ 
→ 
→ 
→ 
